Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5-29; PMID:25559415; http://dx.doi.org/10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64:52-62; PMID:24114568; http://dx.doi.org/10.3322/caac.21203
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363:1938-48; PMID:21067385; http://dx.doi.org/10.1056/NEJMra1001389
   PubMed Web of Science ®Google Scholar
• Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 2012; 133:831-41; PMID:22147079; http://dx.doi.org/10.1007/s10549-011-1891-6
   PubMed Web of Science ®Google Scholar
• Pathy NB, Yip CH, Taib NA, Hartman M, Saxena N, Iau P, Bulgiba AM, Lee SC, Lim SE, Wong JE, et al. Singapore-Malaysia Breast Cancer Working Group. Breast cancer in a multi-ethnic Asian setting: results from the Singapore-Malaysia hospital-based breast cancer registry. Breast 2011; 20(Suppl 2):S75-80; PMID:21316967; http://dx.doi.org/10.1016/j.breast.2011.01.015
   PubMedGoogle Scholar
• Kwong A, Mang OW, Wong CH, Chau WW, Law SC. Hong Kong Breast Cancer Research Group. Breast cancer in Hong Kong, Southern China: the first population-based analysis of epidemiological characteristics, stage-specific, cancer-specific, and disease-free survival in breast cancer patients:1997–2001. Ann Surg Oncol 2011; 18:3072-8; PMID:21847700; http://dx.doi.org/10.1245/s10434-011-1960-4
   PubMed Web of Science ®Google Scholar
• Raina V, Bhutani M, Bedi R, Sharma A, Deo SV, Shukla NK, Mohanti BK, Rath GK. Clinical features and prognostic factors of early breast cancer at a major cancer center in North India. Indian J Cancer 2005; 42:40-5; PMID:15805691; http://dx.doi.org/10.4103/0019-509X.15099
   PubMedGoogle Scholar
• Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, Wong NS, Yip GW, Bay BH, Tan PH. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 2011; 13:R35; PMID:21457545; http://dx.doi.org/10.1186/bcr2857
   PubMed Web of Science ®Google Scholar
• Amir E, Ocana A, Freedman O, Clemons M, Seruga B. Chemotherapy:dose-dense treatment for triple-negative breast cancer. Nat Rev Clin Oncol 2010; 7:79-80; PMID:20118978; http://dx.doi.org/10.1038/nrclinonc.2009.231
   PubMed Web of Science ®Google Scholar
• Hama Y, Nakagawa K. Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases. Breast Cancer 2013; 20:191-3; PMID:20082162; http://dx.doi.org/10.1007/s12282-009-0195-8
   PubMed Web of Science ®Google Scholar
• Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer:disease entity or title of convenience?. Nat Rev Clin Oncol 2010; 7:683-92; PMID:20877296; http://dx.doi.org/10.1038/nrclinonc.2010.154
   PubMed Web of Science ®Google Scholar
• de Gelder R, van As E, Tilanus-Linthorst MM, Bartels CC, Boer R, Draisma G, de Koning HJ. Breast cancer screening: evidence for false reassurance?. Int J Cancer 2008; 123:680-6; PMID:18484587; http://dx.doi.org/10.1002/ijc.23540
   PubMed Web of Science ®Google Scholar
• Kroman NT, Grinsted P, Nielsen NS. Symptoms and diagnostic work-up in breast cancer. Ugeskr Laeger 2007; 169:2980-1; PMID:17953874
   PubMedGoogle Scholar
• Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003; 361:1405-10; PMID:12727392; http://dx.doi.org/10.1016/S0140-6736(03)13143-1
   PubMed Web of Science ®Google Scholar
• Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005; 293:1245-56; PMID:15755947; http://dx.doi.org/10.1001/jama.293.10.1245
   PubMed Web of Science ®Google Scholar
• Chérel P, Hagay C, Benaim B, De Maulmont C, Engerand S, Langer A, Talma V. Mammographic evaluation of dense breasts:techniques and limits. J Radiol 2008; 89:1156-68; PMID:18772800; http://dx.doi.org/10.1016/S0221-0363(08)73926-X
   PubMedGoogle Scholar
• Ding J, Warren R, Warsi I, Day N, Thompson D, Brady M, Tromans C, Highnam R, Easton D. Evaluating the effectiveness of using standard mammogram form to predict breast cancer risk: case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17:1074-81; PMID:18483328; http://dx.doi.org/10.1158/1055-9965.EPI-07-2634
   PubMed Web of Science ®Google Scholar
• Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007; 43:1905-17; PMID:17681781; http://dx.doi.org/10.1016/j.ejca.2007.06.007
   PubMed Web of Science ®Google Scholar
• Zeidan BA, Townsend PA. SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res 2008; 10:107; PMID:18644101; http://dx.doi.org/10.1186/bcr2107
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346-52; PMID:22522925; http://dx.doi.org/10.1038/nature10983
   PubMed Web of Science ®Google Scholar
• Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008; 5:588-99; PMID:18695711; http://dx.doi.org/10.1038/ncponc1187
   PubMedGoogle Scholar
• Engwegen JY, Alberts M, Knol JC, Jimenez CR, Depla AC, Tuynman H, van Heukelem HA, Snel P, Smits ME, Cats A, et al. Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer. Proteomics Clin Appl 2008; 2:936-45; PMID:21136891; http://dx.doi.org/10.1002/prca.200780068
   PubMed Web of Science ®Google Scholar
• Gast MC, van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clin Chem Lab Med 2009; 47:694-705; PMID:19416081; http://dx.doi.org/10.1515/CCLM.2009.151
   PubMed Web of Science ®Google Scholar
• Hsieh SY, Chen RK, Pan YH, Lee HL. Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 2006; 6:3189-98; PMID:16586434; http://dx.doi.org/10.1002/pmic.200500535
   PubMed Web of Science ®Google Scholar
• Timms JF, Arslan-Low E, Gentry-Maharaj A, Luo Z, T'Jampens D, Podust VN, Ford J, Fung ET, Gammerman A, Jacobs I, et al. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clin Chem 2007; 53:645-56; PMID:17303688; http://dx.doi.org/10.1373/clinchem.2006.080101
   PubMed Web of Science ®Google Scholar
• Zeidan BA, Cutress RI, Murray N, Coulton GR, Hastie C, Packham G, Townsend PA. Proteomic analysis of archival breast cancer serum. Cancer Genomics Proteomics 2009; 6:141-7; PMID:19487543
   PubMedGoogle Scholar
• Smith L, Lind MJ, Welham KJ, Cawkwell L. Cancer Biology Proteomics Group. Cancer proteomics and its application to discovery of therapy response markers in human cancer. Cancer 2006; 107:232-41; PMID:16752413; http://dx.doi.org/10.1002/cncr.22000
   PubMed Web of Science ®Google Scholar
• Diamond DL, Proll SC, Jacobs JM, Chan EY, Camp DG 2nd, Smith RD, Katze MG. HepatoProteomics: applying proteomic technologies to the study of liver function and disease. Hepatology 2006; 44:299-308; PMID:16871559; http://dx.doi.org/10.1002/hep.21318
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Schlegl J, Hahne H, Moghaddas Gholami A, Lieberenz M, Savitski MM, Ziegler E, Butzmann L, Gessulat S, Marx H, et al. Mass-spectrometry-based draft of the human proteome. Nature 2014; 509:582-7; PMID:24870543; http://dx.doi.org/10.1038/nature13319
   PubMed Web of Science ®Google Scholar
• Nilsson T, Mann M, Aebersold R, Yates JR 3rd, Bairoch A, Bergeron JJ. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 2010; 7:681-5; PMID:20805795; http://dx.doi.org/10.1038/nmeth0910-681
   PubMed Web of Science ®Google Scholar
• Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, Madugundu AK, Kelkar DS, Isserlin R, Jain S, et al. A draft map of the human proteome. Nature 2014; 509:575-81; PMID:24870542; http://dx.doi.org/10.1038/nature13302
   PubMed Web of Science ®Google Scholar
• Tan HT, Lee YH, Chung MC. Cancer proteomics. Mass Spectrom Rev 2012; 31:583-605; PMID:22422534; http://dx.doi.org/10.1002/mas.20356
   PubMed Web of Science ®Google Scholar
• George IS, Fennell AY, Haynes PA. Protein identification and quantification from riverbank grape, Vitis riparia: Comparing SDS-PAGE and FASP-GPF techniques for shotgun proteomic analysis. Proteomics 2015; 15:3061-5; PMID:25929842; http://dx.doi.org/10.1002/pmic.201500085
   PubMed Web of Science ®Google Scholar
• Kim J, Kim SH, Lee SU, Ha GH, Kang DG, Ha NY, Ahn JS, Cho HY, Kang SJ, Lee YJ, et al. Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis 2002; 23:4142-56; PMID:12481271; http://dx.doi.org/10.1002/elps.200290032
   PubMed Web of Science ®Google Scholar
• Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008; 14:470-7; PMID:18223221; http://dx.doi.org/10.1158/1078-0432.CCR-07-0586
   PubMed Web of Science ®Google Scholar
• Feng Y, Tian ZM, Wan MX, Zheng ZB. Protein profile of human hepatocarcinoma cell line SMMC-7721: identification and functional analysis. World J Gastroenterol 2007; 13:2608-14; PMID:17552011; http://dx.doi.org/10.3748/wjg.v13.i18.2608
   PubMed Web of Science ®Google Scholar
• Li C, Chen Z, Xiao Z, Wu X, Zhan X, Zhang X, Li M, Li J, Feng X, Liang S, et al. Comparative proteomics analysis of human lung squamous carcinoma. Biochem Biophys Res Commun 2003; 309:253-60; PMID:12943690; http://dx.doi.org/10.1016/j.bbrc.2003.08.001
   PubMed Web of Science ®Google Scholar
• Au JS, Cho WC, Yip TT, Law SC. Proteomic approach to biomarker discovery in cancer tissue from lung adenocarcinoma among nonsmoking Chinese women in Hong Kong. Cancer Invest 2008; 26:128-35; PMID:18259942; http://dx.doi.org/10.1080/07357900701788031
   PubMed Web of Science ®Google Scholar
• Xiao X, Liu D, Tang Y, Guo F, Xia L, Liu J, He D. Development of proteomic patterns for detecting lung cancer. Dis Markers 2003–2004; 19:33-9; PMID:14757945; http://dx.doi.org/10.1155/2003/278152
   PubMed Web of Science ®Google Scholar
• Lin JF, Xu J, Tian HY, Gao X, Chen QX, Gu Q, Xu GJ, Song JD, Zhao FK. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer 2007; 121:2596-605; PMID:17722004; http://dx.doi.org/10.1002/ijc.23016
   PubMed Web of Science ®Google Scholar
• Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62:3609-14; PMID:12097261
   PubMed Web of Science ®Google Scholar
• Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48:1835-43; PMID:12324514
   PubMed Web of Science ®Google Scholar
• Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC. Use of a combination of approaches to identify and validate relevant tumor associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 2008; 14:764-71; PMID:18245537; http://dx.doi.org/10.1158/1078-0432.CCR-07-0856
   PubMed Web of Science ®Google Scholar
• Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004; 76:1560-70; PMID:15018552; http://dx.doi.org/10.1021/ac0352171
   PubMed Web of Science ®Google Scholar
• Schulz DM, Böllner C, Thomas G, Atkinson M, Esposito I, Höfler H, Aubele M. Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J Proteome Res 2009; 8:3430-8; PMID:19485423; http://dx.doi.org/10.1021/pr900071h
   PubMed Web of Science ®Google Scholar
• He J, Whelan SA, Lu M, Shen D, Chung DU, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response. Int J Proteomics 2011; 2011:896476; PMID:22110952; http://dx.doi.org/10.1155/2011/896476
   PubMedGoogle Scholar
• Cabezón T, Gromova I, Gromov P, Serizawa R, Timmermans Wielenga V, Kroman N, Celis JE, Moreira JM. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies MageA4 as potential therapeutic target in estrogen receptor negative breast cancer. Mol Cell Proteomics 2013; 12:381-94; PMID:23172894; http://dx.doi.org/10.1074/mcp.M112.019786
   PubMed Web of Science ®Google Scholar
• Lu M, Whelan SA, He J, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer. Clin Proteomics 2010; 6:93-103; PMID:20930921; http://dx.doi.org/10.1007/s12014-010-9052-1
   PubMedGoogle Scholar
• Liu AN, Sun P, Liu JN, Yu CY, Qu HJ, Jiao AH, Zhang LM. Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer. Tumour Biol 2014; 35:9751-7; PMID:24972967; http://dx.doi.org/10.1007/s13277-014-2221-5
   PubMed Web of Science ®Google Scholar
• Fan Y, Shi L, Liu Q, Dong R, Zhang Q, Yang S, Fan Y, Yang H, Wu P, Yu J, et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer 2009; 8:79; PMID:19785722; http://dx.doi.org/10.1186/1476-4598-8-79
   PubMed Web of Science ®Google Scholar
• Wang J, Wang L, Zhang D, Fan Y, Jia Z, Qin P, Yu J, Zheng S, Yang F. Identification of potential serum biomarkers for Wilms tumor after excluding confounding effects of common systemic inflammatory factors. Mol Biol Rep 2012; 39:5095-104; PMID:22160518; http://dx.doi.org/10.1007/s11033-011-1305-1
   PubMed Web of Science ®Google Scholar
• Fan Y, Wang J, Yang Y, Liu Q, Fan Y, Yu J, Zheng S, Li M, Wang J. Detection and identification of potential biomarkers of breast cancer. J Cancer Res Clin Oncol 2010; 136:1243-54; PMID:20237941; http://dx.doi.org/10.1007/s00432-010-0775-1
   PubMed Web of Science ®Google Scholar
• Poste G. Bring on the biomarkers. Nature 2011; 469:156-7; PMID:21228852; http://dx.doi.org/10.1038/469156a
   PubMed Web of Science ®Google Scholar
• Chung L, Baxter RC. Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays. Expert Rev Proteomics 2012; 9:599-614; PMID:23256671; http://dx.doi.org/10.1586/epr.12.62
   PubMed Web of Science ®Google Scholar
• Puppione DL, Ryan CM, Bassilian S, Souda P, Xiao X, Ryder OA, Whitelegge JP. Detection of two distinct forms of apoC-I in great apes. Comp Biochem Physiol Part D Genomics Proteomics 2010; 5:73-9; PMID:20209111; http://dx.doi.org/10.1016/j.cbd.2009.12.003
   PubMed Web of Science ®Google Scholar
• Larsson M, Vorrsjö E, Talmud P, Lookene A, Olivecrona G. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem 2013; 288:33997-4008; PMID:24121499; http://dx.doi.org/10.1074/jbc.M113.495366
   PubMed Web of Science ®Google Scholar
• Chung L, Moore K, Phillips L, Boyle FM, Marsh DJ, Baxter RC. Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res 2014; 16:R63; PMID:24935269; http://dx.doi.org/10.1186/bcr3676
   PubMed Web of Science ®Google Scholar
• Chung L, Phillips L, Lin MZ, Moore K, Marsh DJ, Boyle FM, Baxter RC. A novel truncated form of S100P predicts disease-free survival in patients with lymph node positive breast cancer. Cancer Lett 2015; 368:64-70; PMID:26276712; http://dx.doi.org/10.1016/j.canlet.2015.07.046
   PubMed Web of Science ®Google Scholar
• Sun L, Li L, Li Z, Hong S, Yang Q, Qu X, Kong B. Alterations in the serum proteome profile during the development of ovarian cancer. Int J Oncol 2014; 45:2495-501; PMID:25340615; http://dx.doi.org/10.3892/ijo.2014.2675
   PubMed Web of Science ®Google Scholar
• De Bock M, Beguin Y, Leprince P, Willems E, Baron F, Deroyer C, Seidel L, Cavalier E, de Seny D, Malaise M, et al. Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkers. Talanta 2014; 125:265-75; PMID:24840443; http://dx.doi.org/10.1016/j.talanta.2014.03.017
   PubMed Web of Science ®Google Scholar
• Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D, Parsons-Wingerter P, Rayman P, et al. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem 2013; 288:21237-52; PMID:23720750; http://dx.doi.org/10.1074/jbc.M113.468967
   PubMed Web of Science ®Google Scholar
• Kim MY, Yoo BC, Cho JY. Ginsenoside-Rp1-induced apolipoprotein A-1 expression in the LoVo human colon cancer cell line. J Ginseng Res 2014; 38:251-5; PMID:25379004; http://dx.doi.org/10.1016/j.jgr.2014.06.003
   PubMed Web of Science ®Google Scholar
• Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, Ng C, Wagner A, Hough G, Farias-Eisner G, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA 2010; 107:19997-20002; PMID:21041624; http://dx.doi.org/10.1073/pnas.1009010107
   PubMed Web of Science ®Google Scholar
• Hsu MC, Lee KT, Hsiao WC, Wu CH, Sun HY, Lin IL, Young KC. The dyslipidemia-associated SNP on the APOA1/C3/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: a 10-year follow-up study. BMC Cancer 2013; 13:330; PMID:23829168; http://dx.doi.org/10.1186/1471-2407-13-330
   PubMed Web of Science ®Google Scholar
• Kohan AB. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2015; 22:119-25; PMID:25692924; http://dx.doi.org/10.1097/MED.0000000000000136
   PubMed Web of Science ®Google Scholar
• Sol EM, Sundsten T, Bergsten P. Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells. Lipids Health Dis 2009; 8:3; PMID:19196457; http://dx.doi.org/10.1186/1476-511X-8-3
   PubMed Web of Science ®Google Scholar
• Adham SA, Al Rawahi H, Habib S, Al Moundhri MS, Viloria-Petit A, Coomber BL. Modeling of hypo/hyperglycemia and their impact on breast cancer progression related molecules. PLoS One 2014; 9:e113103; PMID:25401697; http://dx.doi.org/10.1371/journal.pone.0113103
   PubMedGoogle Scholar
• Kim BK, Chang Y, Ahn J, Jung HS, Kim CW, Yun KE, Kwon MJ, Suh BS, Chung EC, Shin H, et al. Metabolic syndrome, insulin resistance, and mammographic density in pre- and postmenopausal women. Breast Cancer Res Treat 2015; 153:425-34; PMID:26277917; http://dx.doi.org/10.1007/s10549-015-3544-7
   PubMed Web of Science ®Google Scholar
• Moore LE, Brennan P, Karami S, Menashe I, Berndt SI, Dong LM, Meisner A, Yeager M, Chanock S, Colt J, et al. Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk. Cancer Res 2009; 69:8001-8; PMID:19808960; http://dx.doi.org/10.1158/0008-5472.CAN-09-1734
   PubMed Web of Science ®Google Scholar
• Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, Kimura F, Shimizu H, Tomonaga T, Nomura F, Miyazaki M. Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene 2008; 27:2810-22; PMID:18037960; http://dx.doi.org/10.1038/sj.onc.1210951
   PubMed Web of Science ®Google Scholar
• McNeal CJ, Chatterjee S, Hou J, Worthy LS, Larner CD, Macfarlane RD, Alaupovic P, Brocia RW. Human HDL containing a novel apoC-I isoform induces smooth muscle cell apoptosis. Cardiovasc Res 2013; 98:83-93; PMID:23354389; http://dx.doi.org/10.1093/cvr/cvt014
   PubMed Web of Science ®Google Scholar
• Kolmakova A, Kwiterovich P, Virgil D, Alaupovic P, Knight-Gibson C, Martin SF, Chatterjee S. Apolipoprotein C-I induces apoptosis in human aortic smooth muscle cells via recruiting neutral sphingomyelinase. Arterioscler Thromb Vasc Biol 2004; 24:264-9; PMID:14670935; http://dx.doi.org/10.1161/01.ATV.0000112036.72200.ac
   PubMed Web of Science ®Google Scholar
• Opstal-van Winden AW, Krop EJ, Kåredal MH, Gast MC, Lindh CH, Jeppsson MC, Jönsson BA, Grobbee DE, Peeters PH, Beijnen JH, et al. Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. BMC Cancer 2011; 11:381; PMID:21871081; http://dx.doi.org/10.1186/1471-2407-11-381
   PubMed Web of Science ®Google Scholar